Cargando…

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review

AIM: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). METHODS: The study included patients with schizophrenia and related psychotic di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishi, Taro, Sakuma, Kenji, Okuya, Makoto, Hatano, Masakazu, Iwata, Nakao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Micro Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411314/ https://www.ncbi.nlm.nih.gov/pubmed/34212530 http://dx.doi.org/10.1002/npr2.12192

Ejemplares similares

Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

Body composition in Japanese patients with psychiatric disorders: A cross‐sectional study
por: Kishi, Taro, et al.
Publicado: (2021)

Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta‐analysis of double‐blind, randomized, placebo‐controlled trials with an enrichment design
por: Oya, Kazuto, et al.
Publicado: (2019)

Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression
por: Kishi, Taro, et al.
Publicado: (2022)

Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
por: Kishi, Taro, et al.
Publicado: (2019)

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
por: Kishi, Taro, et al.
Publicado: (2019)

A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
por: Kishi, Taro, et al.
Publicado: (2023)

Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2020)

Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2016)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao, Yueren, et al.
Publicado: (2013)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia
por: Hatano, Masakazu, et al.
Publicado: (2017)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi, Taro, et al.
Publicado: (2014)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
por: Mahlich, Jörg, et al.
Publicado: (2020)

Effects of age on suicide attempts by medication in patients transferred to the emergency rooms of two advanced medical centers: A retrospective chart review of the DJ project
por: Sasaki, Taro, et al.
Publicado: (2023)

Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Effect of antipsychotics on serum lithium levels and white blood cell counts
por: Obara, Ryo, et al.
Publicado: (2021)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi, Taro, et al.
Publicado: (2017)

Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
por: Hatano, Masakazu, et al.
Publicado: (2021)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10
por: Tatini, Lorenzo, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

What outcomes in community mental health research are important to caregivers of people with schizophrenia? An exploratory qualitative analysis of an online survey
por: Yasuma, Naonori, et al.
Publicado: (2022)

Care difficulties and burden during COVID‐19 pandemic lockdowns among caregivers of people with schizophrenia: A cross‐sectional study
por: Yasuma, Naonori, et al.
Publicado: (2021)

Comparison of eye movements in schizophrenia and autism spectrum disorder
por: Shiino, Tomoko, et al.
Publicado: (2019)

Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review
por: Kishi, Taro, et al.
Publicado: (2021)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia
por: Wei, Yue, et al.
Publicado: (2022)

Prescription patterns in patients with schizophrenia in Japan: First‐quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project
por: Ichihashi, Kayo, et al.
Publicado: (2020)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jtbsv1515jf1imlc6gm3oefdp1